Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: A phase 2 trial of the eastern cooperative oncology group

Athanassios Argiris, Ashley Buchanan, Bruce Brockstein, Jill Kolesar, Musie Ghebremichael, Michael Pins, Kristine Hahn, Rita Axelrod, Arlene Forastiere

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. Patients received docetaxel 35 mg/m2 and irinotecan 60 mg/m2, intravenously, on Days 1 and 8, every 21 days, until disease progression. The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. RESULTS: Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were paclitaxel-exposed. In Group A, 3 (15%) patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). CONCLUSIONS: Docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or platinum-based regimens.

Original languageEnglish (US)
Pages (from-to)4504-4513
Number of pages10
JournalCancer
Volume115
Issue number19
DOIs
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

irinotecan
docetaxel
Head and Neck Neoplasms
Vascular Endothelial Growth Factor A
Disease-Free Survival
Drug Therapy

Keywords

  • Docetaxel
  • Head and neck cancer
  • Irinotecan
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Argiris, A., Buchanan, A., Brockstein, B., Kolesar, J., Ghebremichael, M., Pins, M., ... Forastiere, A. (2009). Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: A phase 2 trial of the eastern cooperative oncology group. Cancer, 115(19), 4504-4513. https://doi.org/10.1002/cncr.24528

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer : A phase 2 trial of the eastern cooperative oncology group. / Argiris, Athanassios; Buchanan, Ashley; Brockstein, Bruce; Kolesar, Jill; Ghebremichael, Musie; Pins, Michael; Hahn, Kristine; Axelrod, Rita; Forastiere, Arlene.

In: Cancer, Vol. 115, No. 19, 01.10.2009, p. 4504-4513.

Research output: Contribution to journalArticle

Argiris, A, Buchanan, A, Brockstein, B, Kolesar, J, Ghebremichael, M, Pins, M, Hahn, K, Axelrod, R & Forastiere, A 2009, 'Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: A phase 2 trial of the eastern cooperative oncology group', Cancer, vol. 115, no. 19, pp. 4504-4513. https://doi.org/10.1002/cncr.24528
Argiris, Athanassios ; Buchanan, Ashley ; Brockstein, Bruce ; Kolesar, Jill ; Ghebremichael, Musie ; Pins, Michael ; Hahn, Kristine ; Axelrod, Rita ; Forastiere, Arlene. / Docetaxel and irinotecan in recurrent or metastatic head and neck cancer : A phase 2 trial of the eastern cooperative oncology group. In: Cancer. 2009 ; Vol. 115, No. 19. pp. 4504-4513.
@article{7f18eb4444474215bbafc36ac9248d02,
title = "Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: A phase 2 trial of the eastern cooperative oncology group",
abstract = "BACKGROUND: Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. Patients received docetaxel 35 mg/m2 and irinotecan 60 mg/m2, intravenously, on Days 1 and 8, every 21 days, until disease progression. The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. RESULTS: Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73{\%} of patients had distant metastasis, and 60{\%} were paclitaxel-exposed. In Group A, 3 (15{\%}) patients achieved a partial response; in Group B, 1 (3{\%}) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). CONCLUSIONS: Docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or platinum-based regimens.",
keywords = "Docetaxel, Head and neck cancer, Irinotecan, Vascular endothelial growth factor",
author = "Athanassios Argiris and Ashley Buchanan and Bruce Brockstein and Jill Kolesar and Musie Ghebremichael and Michael Pins and Kristine Hahn and Rita Axelrod and Arlene Forastiere",
year = "2009",
month = "10",
day = "1",
doi = "10.1002/cncr.24528",
language = "English (US)",
volume = "115",
pages = "4504--4513",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - Docetaxel and irinotecan in recurrent or metastatic head and neck cancer

T2 - A phase 2 trial of the eastern cooperative oncology group

AU - Argiris, Athanassios

AU - Buchanan, Ashley

AU - Brockstein, Bruce

AU - Kolesar, Jill

AU - Ghebremichael, Musie

AU - Pins, Michael

AU - Hahn, Kristine

AU - Axelrod, Rita

AU - Forastiere, Arlene

PY - 2009/10/1

Y1 - 2009/10/1

N2 - BACKGROUND: Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. Patients received docetaxel 35 mg/m2 and irinotecan 60 mg/m2, intravenously, on Days 1 and 8, every 21 days, until disease progression. The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. RESULTS: Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were paclitaxel-exposed. In Group A, 3 (15%) patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). CONCLUSIONS: Docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or platinum-based regimens.

AB - BACKGROUND: Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. Patients received docetaxel 35 mg/m2 and irinotecan 60 mg/m2, intravenously, on Days 1 and 8, every 21 days, until disease progression. The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. RESULTS: Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were paclitaxel-exposed. In Group A, 3 (15%) patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). CONCLUSIONS: Docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or platinum-based regimens.

KW - Docetaxel

KW - Head and neck cancer

KW - Irinotecan

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=70349295970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349295970&partnerID=8YFLogxK

U2 - 10.1002/cncr.24528

DO - 10.1002/cncr.24528

M3 - Article

C2 - 19634157

AN - SCOPUS:70349295970

VL - 115

SP - 4504

EP - 4513

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -